CD133: A Thorough British Guide to the Stem Cell Marker and Its Role in Medicine
CD133 is one of the most widely recognised markers in contemporary biology, frequently discussed in the same breath as stem cells, cancer biology and regenerative medicine. Known formally as prominin-1 and encoded by the PROM1 gene, CD133 sits on the surface of various cell types and has become a touchstone in both research and clinical discussions. This article provides a comprehensive, reader-friendly exploration of CD133, its biology, how it is detected, and why it matters in both healthy tissue and disease. We will also consider the complexities, limitations, and future directions that shape how scientists and clinicians use CD133 in practice.
CD133: The Basics, Explained
What is CD133?
CD133 is a transmembrane glycoprotein that sits on the plasma membrane of cells. It is encoded by the PROM1 gene and belongs to the prominin family. The molecule is characterised by its five-transmembrane topology and extracellular loops that can be heavily glycosylated. In the literature you will often see CD133 referred to as prominin-1. In many studies, researchers use the shorthand CD133 to denote the protein, while PROM1 is used when discussing the gene and its regulatory mechanisms. The term AC133 is frequently encountered in older antibody literature and refers to a particular epitope recognised by specific anti-CD133 antibodies. Understanding these naming conventions helps researchers avoid confusion when comparing studies that use different antibodies or detection methods.
Expression patterns and tissue distribution
CD133 is expressed in a variety of stem and progenitor cell populations across tissues, including haematopoietic, neural, epithelial and endothelial lines. In normal physiology, CD133 marks cells with higher regenerative potential in tissues such as the brain, gut and skin. Expression can be dynamic, changing with developmental stage, tissue context and environmental cues. Not every stem or progenitor cell population expresses CD133 uniformly, and the level of expression can be influenced by microenvironmental factors such as hypoxia or inflammatory signals. For this reason, CD133 is best interpreted as part of a broader panel of markers rather than a singular, definitive indicator of stemness.
The biology behind CD133 and its role in cells
CD133 is believed to participate in the maintenance of stem cell compartments and may influence cell polarity, membrane architecture and signal compartmentalisation. The protein’s extracellular loops and glycan modifications can affect how cells interact with their niche and respond to signals that govern self-renewal and differentiation. In experimental systems, altering CD133 expression or function can influence how cells proliferate and differentiate, although the precise mechanisms remain an active area of investigation. In short, CD133 is a functional marker that is also a biomolecule with roles in cell biology beyond a simple “flag” for stemness.
CD133 as a Marker of Stemness: How and Why It Is Used
The historical significance of CD133 in stem cell biology
CD133 rose to prominence in the late 1990s and early 2000s as a tool for isolating stem and progenitor cells in several tissues. The antibody AC133, used in early work, helped researchers enrich for cell populations with strong regenerative capacity. Since then, the field has evolved to recognise that CD133 is a useful enrichment marker but not a universal definition of stemness. In regenerative medicine, researchers often combine CD133 with other markers and functional assays to establish a more accurate profile of a cell’s potential.
CD133 in neural, haematopoietic and epithelial tissues
In the neural system, CD133-positive cells are frequently enriched for neural stem and progenitor activity, contributing to neural repair and brain development research. In the haematopoietic system, CD133 marks subsets of progenitor cells with the capacity to give rise to mature blood lineages, though its expression is not exclusive to stem cells and can appear in more differentiated cells under certain circumstances. Epithelial tissues, including the intestinal lining and renal tubules, also display CD133-positive populations associated with regenerative potential. Across these contexts, CD133 is best viewed as a useful marker within a toolbox, rather than a standalone indicator of stemness.
CD133 versus other stem cell markers
Many laboratories use a panel of markers to identify stem or progenitor cells. In neural tissue, for example, combinations such as CD133 with Nestin or Sox2 can strengthen confidence in stem cell identity. In haematopoiesis, CD133 is often used alongside CD34 and CD38 to discern primitive populations. Each marker contributes unique information about the cell’s state, and the choice of markers can depend on tissue type, experimental aims and available detection methods. The key takeaway is that CD133 is valuable but most informative when considered within a broader phenotypic and functional framework.
CD133 in Cancer: Cancer Stem Cells and Beyond
Why CD133 attracts attention in oncology
CD133 has become a focal point in cancer research because certain tumours appear to contain a subpopulation of CD133-positive cells believed to drive tumour initiation, growth and relapse. These cells are commonly referred to as cancer stem cells (CSCs). The hypothesis is that CSCs harbour enhanced resistance to conventional therapies, enabling tumour regrowth after treatment. CD133 has been studied as a potential biomarker to identify and isolate these CSCs, with the aim of informing prognosis and guiding targeted therapies.
Clinical implications and debates
While CD133 offers a tantalising link to CSC biology, the picture is nuanced. CD133 expression can be found in non-tumour cells and may be downregulated or upregulated depending on treatment, microenvironment, and disease stage. Not all cancers display a clear, uniform CD133-positive CSC population, and some tumours with poor prognosis do not rely on CD133 in the same way as others. Consequently, researchers emphasise multimarker strategies and functional assays—such as sphere formation, serial transplantation and dye-exclusion methods—to corroborate stemness in cancer cells. In practice, CD133 contributes to a broader framework for understanding tumour hierarchy rather than serving as a single, definitive prognostic marker.
Controversies and limitations
The field recognises several caveats. CD133 expression can be unstable or context-dependent, and different antibody clones target distinct epitopes, which can yield variable detection results. Additionally, some normal tissues can express CD133 at baseline, complicating interpretations in both diagnostic and therapeutic settings. As a result, researchers advocate for careful validation of antibodies, consistent gating strategies in flow cytometry and the use of functional assays to validate stem-like properties in CD133-positive populations.
Detecting CD133: Methods, Clones and Best Practices
Flow cytometry and cell sorting
Flow cytometry is the workhorse technique for identifying CD133-positive cells. Antibodies against CD133 bind to extracellular epitopes, allowing live sorting of CD133-positive fractions. Important considerations include selecting the appropriate antibody clone, understanding epitope recognition (for instance, AC133 or other clones), choosing the correct isotype controls, and ensuring cell viability during staining. Proper compensation, fluorescence minus one (FMO) controls, and robust gating strategies are essential for reproducible results. In studies where CD133 is used to enrich stem-like cells, researchers often pair the marker with additional surface proteins (for example CD34, CD90 or CD29) to delineate subpopulations more precisely.
Immunohistochemistry and tissue-based detection
Immunohistochemistry (IHC) enables localization of CD133 within tissue sections, highlighting spatial distribution and architecture. Tissue processing, antigen retrieval methods and antibody specificity all influence staining quality. Different CD133 antibodies target distinct epitopes, which can affect detection in fixed tissues. Sub-cellular localisation and the interpretation of staining intensity require careful standardisation and often corroboration with molecular assays to confirm cell identity and state.
Real-time PCR and transcript level analysis
Measuring PROM1 transcript levels via real-time PCR provides a complementary perspective to protein-based detection. Transcript data can illuminate regulation at the gene level and help distinguish when protein expression does not correlate with mRNA abundance. However, mRNA presence does not always translate to surface protein expression, particularly for membrane proteins where trafficking and glycosylation modify detectability. Therefore, transcriptional analysis should be interpreted alongside protein-level measurements.
Epitope variability and antibody clones
A practical challenge in CD133 research is clone-to-clone variability. Different antibodies may recognise distinct extracellular epitopes, leading to discrepancies in the fraction of CD133-positive cells reported across studies. This variability is particularly relevant when comparing data from separate laboratories or when attempting to replicate findings. The best practice is to clearly report the antibody clone, staining protocol, and gating strategy, and where possible, to validate findings with a second, independent antibody targeting a different epitope.
CD133 in Regenerative Medicine and Stem Cell Therapies
Potential roles in tissue regeneration
CD133-positive cells have been explored for their regenerative potential in multiple tissues, including neural, cardiac and hepatic systems. In regenerative medicine, isolating CD133-positive populations can enrich for cells with higher proliferative capacity and greater plasticity, potentially improving engraftment and tissue repair. Nevertheless, the translational path from bench to bedside is complex, requiring rigorous preclinical validation, scalable cell processing, and robust safety testing to avoid adverse outcomes such as unwanted differentiation or tumourigenicity.
Clinical trial considerations
In early-phase trials, investigators may utilise CD133-enriched populations as part of cell therapy strategies. Outcomes of such trials depend on multiple factors, including cell source, culture conditions, delivery method and host environment. It is essential to monitor for long-term safety signals and to interpret results within the context of concomitant therapies and patient heterogeneity. While CD133-guided enrichment can improve the purity of stem-like cells, it does not guarantee therapeutic success on its own; functional performance in relevant disease models remains paramount.
Ethical and regulatory dimensions
The deployment of CD133-positive cells in therapy raises ethical and regulatory considerations common to regenerative medicine. Issues such as consent for cell-based products, donor variability, genetic stability during expansion, and adherence to good manufacturing practice (GMP) standards are critical. Transparent reporting of manufacturing processes, quality controls and clinical endpoints helps ensure patient safety and scientific credibility as the field advances.
Practical Guidance for Researchers Working with CD133
Experimental design and controls
When planning experiments involving CD133, it is prudent to define clear biological questions and choose a multi-marker strategy that reflects tissue context. Include appropriate negative and positive controls, and consider functional readouts such as differentiation capacity, colony-forming assays or in vivo repopulation studies where feasible. Document the antibody clone, lot numbers and experimental conditions to enable reproducibility and cross-lab comparisons.
Sample handling and preparation
Proper sample handling is critical for reliable CD133 detection. For flow cytometry, maintain cell viability, optimise staining concentration and incubation times, and keep samples on ice to limit receptor internalisation. For tissue sections, ensure consistent fixation and processing to preserve epitopes. Because CD133 expression can be influenced by environmental cues, including hypoxia or inflammatory signals, carefully record culture conditions and any treatment variables that could alter expression levels.
Data interpretation and reporting
Interpretation of CD133 data should be presented with context. Report the percentage of CD133-positive cells, median fluorescence intensity (MFI), and the gatings used for flow cytometry. When possible, complement protein-level results with transcriptional data and functional assays. Clearly state limitations, such as clone-specific detection, tissue-specific variability and potential artefacts related to sample quality. Transparent reporting enhances comparability and strengthens the overall evidence base around CD133.
Quality control and validation steps
Robust QC steps include validating antibodies on known positive and negative controls, using orthogonal detection methods, and conducting inter-assay comparisons. Cross-validation with another CD133 antibody clone and, where possible, with PROM1 gene expression measures helps confirm that observed CD133 signals reflect biology rather than artefact. Regular instrument calibration and standardised protocols support consistency across experiments and time.
Future Directions: What Lies Ahead for CD133 Research
Advances in single-cell technologies
Single-cell RNA sequencing and single-cell proteomics are poised to refine our understanding of CD133 expression at unparalleled resolution. These approaches can reveal the heterogeneity of PROM1 expression within tissues, identify co-expressed marker programmes, and uncover how CD133-positive cells differ functionally from their CD133-negative counterparts. Such insights will help in refining strategies for isolation, characterisation and therapeutic application.
Epitope mapping and antibody development
New antibodies targeting alternative, perhaps more stable epitopes on CD133 are likely to emerge, improving detection reliability across fixed tissues and live cells. Epitope mapping studies can identify regions of the molecule that remain accessible under diverse conditions, enabling more consistent assays. In turn, this could reduce variability between studies and enhance cross-platform comparability for the cd133 literature.
Integration with multi-omics and systems biology
Future CD133 research will increasingly integrate genomics, epigenomics, proteomics and metabolomics to build a systems-level view of stem-like cell populations. This holistic approach allows researchers to place CD133 within broader regulatory networks, linking surface expression to signalling pathways, metabolic states and lineage trajectories. Such integration has the potential to uncover new therapeutic targets and refine biomarker panels beyond CD133 alone.
A Practical Catalogue: Quick Reference for Conducting CD133 Work
Choosing your approach
Decide whether you require live cell sorting (flow cytometry) or fixed tissue analysis (IHC). For functional studies, live CD133-positive sorting is often essential. For spatial context in tissues, IHC provides valuable localisation information. If you need to correlate expression with transcription, add RT-qPCR analyses for PROM1.
Antibody strategy
Select a well-characterised antibody clone with documented specificity for your tissue type. If possible, validate with two clones targeting different epitopes to strengthen interpretation. Document clone names, lot numbers and supplier details to support reproducibility.
Controls and thresholds
Implement appropriate controls such as isotype controls, FMO controls and known positive and negative samples. Establish gating thresholds based on controls rather than arbitrary cut-offs, and consider using fluorescence-minus-one controls to determine true CD133 positivity.
Documentation and transparency
Record all experimental parameters, including sample origin, handling time, fixation conditions, antibody concentrations, incubation times and instrument settings. This level of detail facilitates replication and improves the overall reliability of cd133-related findings across laboratories.
Conclusion: The Enduring Relevance of CD133
CD133 remains a central figure in discussions of stem cells, cancer biology and regenerative medicine. While not a universal scalar of stemness, the marker offers valuable insights when used thoughtfully alongside complementary markers and functional tests. By understanding the biology of CD133, mastering robust detection methods, and embracing the complexities and limitations around its interpretation, researchers and clinicians can harness its potential to advance science and patient care. The story of cd133—whether in neural progenitors, haematopoietic cells or tumour biology—continues to evolve, driven by technological progress, rigorous validation and a nuanced appreciation of how this remarkable protein shapes cell fate and tissue regeneration in the human body.